CD19 and acute lymphoblastic leukemia: Because of the unclear molecular mechanisms of resistance to CAR-T therapy in acute lymphoblastic leukemia (ALL), Bai et al. integrated scRNA-seq and CITE-seq to compare responders and CD19-positive relapse patients, during which they confirmed lack of TH2 functionality might be the cause of relapse in CAR-T treatment [209].